Erik P. Sulman

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• [ ¹⁷⁷ Lu]Lu-DOTATATE for Advanced Intracranial Meningioma: The MOMENTUM-1 (RTOG3523) Study Investigators’ Perspective

  Journal of Nuclear Medicine · 2026-06-04

• Final results of a single-arm, open-label, multicenter phase 2 study of the radiopharmaceutical [ ¹⁷⁷ Lu]Lu-DOTA-TATE and [ ⁶⁸ Ga]Ga-DOTA-TATE in adults with advanced intracranial meningioma.

  Journal of Clinical Oncology · 2026-05-27

• Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial

  Journal of Clinical Oncology · 2026-04-14 · 1 citations

• Abstract 7376: HMGB2-mediated radioresistance of glioblastoma stem cells

  Cancer Research · 2026-04-03

• Abstract B010: Common translational challenges in brain tumour therapeutic development identified through a multidisciplinary accelerator programme

  Cancer Research · 2026-03-23

• CCR7 immune cell receptor expression in inflammatory breast cancer

  Scientific Reports · 2026-03-14

• Retrospective analysis of the impact of antidepressants with anti-acid sphingomyelinase activity on survival of patients with glioblastoma

  Journal of Neuro-Oncology · 2026-01-01

• Neurocognitive outcomes in patients with brain metastases: a systematic review

  The Lancet Oncology · 2025-11-25 · 3 citations

• A Clinical Tool to Identify Incidental Meningioma for Early Outpatient Management

  JAMA Oncology · 2025-11-20

• Retrospective analysis of the impact of acid sphingomyelinase inhibiting drugs on survival of patients with glioblastomaPreprint

  Research Square · 2025-11-17

• A framework for using DNA methylation-based modelling for the clinical management of cranial meningioma

  Neuro-Oncology · 2025-11-15 · 1 citations

• Genomic and Epigenomic Signatures Can Distinguish Aggressive Chromophobe Renal Cell Carcinoma from Indolent Renal Oncocytic Tumors in Clinical-grade Samples

  European Urology Oncology · 2025-11-05

• TIP-10. Update on GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma

  Neuro-Oncology · 2025-11-01 · 1 citations

• CTNI-41. RESULTS OF A SINGLE-ARM, OPEN-LABEL, MULTICENTER PHASE 2 STUDY OF THE RADIOPHARMACEUTICAL [177LU]LU-DOTA-TATE IN ADULTS WITH ADVANCED INTRACRANIAL MENINGIOMA

  Neuro-Oncology · 2025-11-01 · 1 citations

• TMIC-41. Anti-Robo1/2 monoclonal antibodies as a novel macrophage-based immunotherapy for glioblastoma

  Neuro-Oncology · 2025-11-01

• IMG-72. [68Ga]Ga-DOTA-TATE PET as imaging biomarker for response assessment and monitoring in patients receiving [177Lu]Lu-DOTA-TATE for advanced intracranial meningioma

  Neuro-Oncology · 2025-11-01

• BIOM-65. A METHYLATION-SIGNATURE OF RADIATION RESPONSE IN GLIOBLASTOMA

  Neuro-Oncology · 2025-11-01

• DDDR-79. A novel, pooled, high-throughput screening of a CNS penetrant compound library identifies potential biomarker-driven therapeutics for glioblastoma

  Neuro-Oncology · 2025-11-01

• TIP-15. Trial in progress: phase IB study of concurrent Azeliragon, a RAGE inhibitor, with craniospinal irradiation in patients with leptomeningeal metastases

  Neuro-Oncology · 2025-11-01

• TIP-11. MOMENTUM-1: a multicenter, randomized, open-label, phase 2 study of [177Lu]Lu-DOTA-TATE in adults with progressive grade 1-3 meningioma (RTOG 3523)

  Neuro-Oncology · 2025-11-01 · 1 citations